Table_5_Amount and Fate of Gas and Oil Discharged at 3400 m Water Depth From a Natural Seep Site in the Southern Gulf of Mexico.XLSX by Miriam Römer (7870673)

“…Concentrations of dissolved methane were highly elevated (∼30,000 nmol/L) directly above the seafloor emission site, but decreased to background concentrations (3–5 nmol/L) within the lowermost 100 m. …”

Table_3_Amount and Fate of Gas and Oil Discharged at 3400 m Water Depth From a Natural Seep Site in the Southern Gulf of Mexico.XLSX by Miriam Römer (7870673)

“…Concentrations of dissolved methane were highly elevated (∼30,000 nmol/L) directly above the seafloor emission site, but decreased to background concentrations (3–5 nmol/L) within the lowermost 100 m. …”

Single-Component Molecular Conductor [Cu(dmdt)₂] with Three-Dimensionally Arranged Magnetic Moments Exhibiting a Coupled Electric and Magnetic Transition by Biao Zhou (287898)

“…Below 265 K, the resistivity (<i>R</i>) increased very slowly with decreasing temperature and then increased rapidly, indicating a transition from a highly conducting state to an insulating state near 95 K. …”

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine <i>versus</i> the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospecti... by Francesca Lombardi (756146)

“…</p><p>Methods</p><p>We performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal vaccine-naïve outpatients, aged 18–65 years with CD4 counts ≥200 cells/μL. …”

Safety and Immunogenicity of a Malaria Vaccine, <em>Plasmodium falciparum</em> AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults by Jinhong Hu (89635)

“…This was a phase I randomized, single-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of the PfCP-2.9 formulated with a novel adjuvant Montanide ISA720. …”

Table_2_Association between perioperative plasma transfusion and in-hospital mortality in patients undergoing surgeries without massive transfusion: A nationwide retrospective coho... by Xiaohan Xu (661043)

“…Background<p>An aggressive plasma transfusion is associated with a decreased mortality in traumatic patients requiring massive transfusion (MT). …”

Table_1_Association between perioperative plasma transfusion and in-hospital mortality in patients undergoing surgeries without massive transfusion: A nationwide retrospective coho... by Xiaohan Xu (661043)

“…Background<p>An aggressive plasma transfusion is associated with a decreased mortality in traumatic patients requiring massive transfusion (MT). …”

Potential Interest in Circulating miR-BART17-5p As a Post-Treatment Biomarker for Prediction of Recurrence in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma by Nobuyuki Hirai (3185838)

“…<div><p>Objectives</p><p>Epstein-Barr virus (EBV)-related micoRNAs (miRNAs), BamHI-A rightward transcripts (BART)-miRNAs, are released in a stable form from viable cells, which are abundant in patients with EBV-positive nasopharyngeal carcinoma (NPC). …”

Table_1_SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype.DOC by Mariele Gatto (444286)

“…<p>Objective: To explore the effects of SERPINB3 administration in murine lupus models with a focus on lupus-like nephritis.</p><p>Methods: 40 NZB/W F1 mice were subdivided into 4 groups and intraperitoneally injected with recombinant SERPINB3 (7.5 μg/0.1 mL or 15 μg/0.1 mL) or PBS (0.1 mL) before (group 1 and 2) or after (group 3 and 4) the development of proteinuria (≥100 mg/dl). …”

Table_2_SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype.DOCX by Mariele Gatto (444286)

“…<p>Objective: To explore the effects of SERPINB3 administration in murine lupus models with a focus on lupus-like nephritis.</p><p>Methods: 40 NZB/W F1 mice were subdivided into 4 groups and intraperitoneally injected with recombinant SERPINB3 (7.5 μg/0.1 mL or 15 μg/0.1 mL) or PBS (0.1 mL) before (group 1 and 2) or after (group 3 and 4) the development of proteinuria (≥100 mg/dl). …”

DataSheet1_Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study.pdf by Fatemeh Khosravi Shadmani (6335432)

“…</p>Methods<p>This study is a test-negative case-control design using data from eight provinces in April, 2021 until March, 2022. …”

Probability of localization in 93.5 dB re 1 <i>μ</i>Pa root median square noise. by Regina A. Guazzo (4543420)

“…In the 50th percentile noise conditions, the probability of localization within the area of the array was approximately 100%. Probability of localization increases as noise levels decrease. …”

Results of the cyclic test experiment on COMP mutant tendons. by Katarzyna A. Piróg (490536)

“…<p><b>A</b>) Stress per cycle plot showing a decrease in force needed to extend mutant tendons to the same strain as the wild type controls. …”

Table_1_Associations among past trauma, post-displacement stressors, and mental health outcomes in Rohingya refugees in Bangladesh: A secondary cross-sectional analysis.pdf by Haley Ritsema (14431125)

“…Trauma (OR = 4.98, 95% CI = 2.20–11.31, p < 0.001) was associated with increased odds of PTSD. Living in a household that received income was associated with decreased odds of PTSD (OR = 0.74, 95% CI = 0.55–1.00, p = 0.05).…”

Image4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image6_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.DOCX by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”